Pinnacle Medicines | $89,000,000 | (Mar 27, 2026)
CurrentClient | $1,250,000 | (Mar 27, 2026)
Mirage | $75,000,000 | (Mar 27, 2026)
Certified by Founder
Lodge
GC Therapeutics
start up
United States
- Cambridge, MA
- 24/09/2024
- Series A
- $65,000,000
GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases.
The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.
- Industry Biotechnology Research
- Website https://www.gc-tx.com/
- LinkedIn https://www.linkedin.com/company/gctx/
Scalvy | $13,900,000 | (Mar 27, 2026)
SIGMAS | $1,000,000 | (Mar 27, 2026)
VITL | $7,500,000 | (Mar 27, 2026)
Payy | $6,000,000 | (Mar 27, 2026)
Conntour | $7,000,000 | (Mar 27, 2026)
KilgourMD | Undisclosed Amount | (Mar 27, 2026)
Terrestrial | $50,000,000 | (Mar 27, 2026)
Krane | $9,000,000 | (Mar 26, 2026)
Zalos (YC F25) | $3,600,000 | (Mar 26, 2026)